Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs)

Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug–drug interactions

(2016) H.J. Burt et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach

(2015) J Snoeys et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective

(2015) HM Jones et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin

(2014) Thomayant Prueksaritanont et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Fluoxetine- and Norfluoxetine-Mediated Complex Drug–Drug Interactions: In Vitro to In Vivo Correlation of Effects on CYP2D6, CYP2C19, and CYP3A4

(2014) J E Sager et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Risks and Benefits of Statin Use in Young People with Type 1 Diabetes

(2014) Petter Bjornstad et al.   Current Diabetes Reports

Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling

(2014) Sieto Bosgra et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine

(2013) M. Jamei et al.   CLINICAL PHARMACOKINETICS

Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations

(2013) Vicky Hsu et al.   CLINICAL PHARMACOKINETICS

ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport-Mediated PK and DDIs in Humans

(2013) M J Zamek-Gliszczynski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers

(2013) Yao Chen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Long-Lasting Inhibitory Effects of Saquinavir and Ritonavir on OATP1B1-Mediated Uptake

(2013) Yoshihisa Shitara et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide

(2013) Manthena V. S. Varma et al.   PHARMACEUTICAL RESEARCH

Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanisticin vitro-in vivoextrapolation of oral drug absorption

(2012) M. D. Harwood et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1

(2012) R Elsby et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Predicting Drug Interaction Potential With a Physiologically Based Pharmacokinetic Model: A Case Study of Telithromycin, a Time-Dependent CYP3A Inhibitor

(2012) Md L T Vieira et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Statin drug interactions and related adverse reactions

(2012) Stefano Bellosta et al.   Expert Opinion On Drug Safety

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

(2012) Manthena V. S. Varma et al.   PHARMACEUTICAL RESEARCH

Identification of the Rate-Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study

(2011) K Maeda et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction

(2011) M. Gertz et al.   DRUG METABOLISM AND DISPOSITION

Prediction of time-dependent CYP3A4 drug–drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover

(2011) K. Rowland Yeo et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation

(2010) R. S. Foti et al.   DRUG METABOLISM AND DISPOSITION

Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin

(2010) R. Amundsen et al.   DRUG METABOLISM AND DISPOSITION

Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

(2010) M. Gertz et al.   DRUG METABOLISM AND DISPOSITION

No clinically relevant drug–drug interactions when dalcetrapib is co-administered with atorvastatin

(2010) Michael Derks et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Effect of Gemfibrozil and Fenofibrate on the Pharmacokinetics of Atorvastatin

(2010) Lloyd R. Whitfield et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population-Based Mechanistic Prediction of Oral Drug Absorption

(2009) Masoud Jamei et al.   AAPS Journal

ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

(2009) J E Keskitalo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Investigation of the Rate-Determining Process in the Hepatic Elimination of HMG-CoA Reductase Inhibitors in Rats and Humans

(2009) T. Watanabe et al.   DRUG METABOLISM AND DISPOSITION

Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes

(2008) S. W. Paine et al.   DRUG METABOLISM AND DISPOSITION

The Quantitative Prediction of CYP-mediated Drug Interaction by Physiologically Based Pharmacokinetic Modeling

(2008) Motohiro Kato et al.   PHARMACEUTICAL RESEARCH

The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15

(2008) Jian Wei Deng et al.   Pharmacogenetics and Genomics